Ovarian Cancer — A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
Citation(s)
An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent